Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 4 results out of 4

Company profileZealand Pharma

Access the most comprehensive report about Zealand Pharma available on the market

Gain competitive edge
Enhance your sales strategy
Gain competitive edge
Enhance your sales strategy

Buy Now

Data Insights

Glepaglutide by Zealand Pharma for Short Bowel Syndrome: Likelihood of Approval

Glepaglutide is under clinical development by Zealand Pharma and currently in Pre-Registration for Short Bowel Syndrome. According to GlobalData, Pre-Registration...

Likelihood of Approval and Phase Transition Success Rate Model - Glepaglutide in Short Bowel Syndrome

Data Insights

ZP-9830 by Zealand Pharma for Chronic Inflammation: Likelihood of Approval

ZP-9830 is under clinical development by Zealand Pharma and currently in Phase I for Chronic Inflammation. According to GlobalData, Phase...

Data Insights

Petrelintide by Zealand Pharma for Obesity: Likelihood of Approval

Petrelintide is under clinical development by Zealand Pharma and currently in Phase I for Obesity. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Petrelintide in Obesity

Data Insights

Dapiglutide by Zealand Pharma for Obesity: Likelihood of Approval

Dapiglutide is under clinical development by Zealand Pharma and currently in Phase II for Obesity. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Dapiglutide in Obesity

Sections

Sections

Sections

Sections

Sections

Company profileZealand Pharma

Glepaglutide by Zealand Pharma for Short Bowel Syndrome: Likelihood of Approval

ZP-9830 by Zealand Pharma for Chronic Inflammation: Likelihood of Approval

Petrelintide by Zealand Pharma for Obesity: Likelihood of Approval

Dapiglutide by Zealand Pharma for Obesity: Likelihood of Approval